Next-Generation CBP Project Based on New Findings from CBP501
First written in FY2016. 26 of 35 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「More recently, based on findings from CBP501 clinical trial data, the company has been generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding.」
The company continues to generate next-generation candidate compounds focused on cancer immunology and cancer stem cells, based on clinical trial data for CBP501. - FY2026-H1RestatedAnnual report
「Of these programs, the company decided to advance CBT005 to preclinical trials, the initial development stage, consisting of nonclinical studies required to obtain the data necessary to apply to initiate clinical trials, and began preparations for this purpose.」
The company continues research and development on its next-generation pipeline using findings from CBP501 and other programs, as well as preparations for preclinical trials of CBT005. - FY2025-H1RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBT005, CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration. Of these programs, the company decided to advance CBT005 to preclinical trials, the initial development stage, consisting of nonclinical studies required to obtain the data necessary to apply to initiate clinical trials, and began preparations for this purpose.」
The company continues research and development on its next-generation pipeline based on findings from CBP501 and other programs, as well as preparations for preclinical trials of CBT005. - FY2024RestatedAnnual report
「More recently, based on findings from CBP501 clinical trial data, the company has been generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding.」
The company continues to generate next-generation candidate compounds focused on cancer immunity, cancer stem cells and other areas based on CBP501 clinical trial data. - FY2024-Q3RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBT005, CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration. Of these programs, the company decided to advance CBT005 to preclinical trials, the initial development stage, consisting of nonclinical studies required to obtain the data necessary to apply to initiate clinical trials, and began preparations for this purpose.」
The company continues research and development on follow-on pipeline programs based on the Next-Generation CBP Project and other initiatives, as well as preparations for preclinical trials of CBT005. - FY2024-Q2AdvancedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBT005, CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration. Of these programs, the company decided to advance CBT005 to preclinical trials, the initial development stage, consisting of nonclinical studies required to obtain the data necessary to apply to initiate clinical trials, and began preparations for this purpose.」
Among the follow-on pipeline programs based on the Next-Generation CBP Project and other initiatives, the company made concrete progress by deciding to advance CBT005 to preclinical trials and beginning preparations. - FY2024-Q1RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBT005, CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues research and development on its next-generation pipeline based on findings from CBP501 and other programs while taking financial constraints into consideration. - FY2023RestatedAnnual report
「The company believes that progress in the clinical development of these compounds and the acquisition of partners enabled its drug discovery engines to establish their concepts through evaluation by external third parties. More recently, based on findings from CBP501 clinical trial data, the company has been generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding.」
The company continues to pursue a policy of using knowledge from the clinical development of CBP501 and other programs to generate next-generation candidate compounds separately from its conventional cell-based phenotypic screening. - FY2023-Q3RestatedAnnual report
「Based on the drug discovery approach that generated the multiple clinical-stage anticancer candidate compounds CBP501 and CBS9106, the knowledge and expertise obtained during their clinical development, and the accumulated basic research focused on cancer immunity, the company believes it can generate multiple anticancer drugs in the future and is conducting related research and development activities.」
The company continues to pursue a research and development policy aimed at generating multiple anticancer drugs based on knowledge and expertise obtained through clinical development and basic research on cancer immunity. - FY2023-Q2RestatedAnnual report
「Based on the drug discovery approach that generated the multiple clinical-stage anticancer candidate compounds CBP501 and CBS9106, the knowledge and expertise obtained during their clinical development, and the accumulated basic research focused on cancer immunity, the company believes it can generate multiple anticancer drugs in the future and is conducting related research and development activities.」
The company continues to pursue a research and development policy aimed at generating multiple anticancer drugs by using knowledge from the clinical development of CBP501 and CBS9106 and basic research on cancer immunity. - FY2022RestatedAnnual report
「To search for and generate novel candidate compounds to follow these two candidate compounds in the pipeline, the company is pursuing discovery research using its proprietary drug screening method and compound generation through the Next-Generation CBP Project based on new findings regarding CBP501, and has obtained the candidate compound CBP-A08.」
The company continues to search for and generate follow-on candidate compounds through its proprietary screening and the Next-Generation CBP Project, and holds CBP-A08. - FY2022-Q3RestatedAnnual report
「Based on the drug discovery approach that generated the multiple clinical-stage anticancer candidate compounds CBP501 and CBS9106, the knowledge and expertise obtained during their clinical development, and the accumulated basic research focused on cancer immunity, the company believes it can generate multiple anticancer drugs in the future and is conducting related research and development activities.」
The company continues to pursue a research and development policy aimed at generating multiple anticancer drugs by using knowledge from the clinical development of CBP501 and CBS9106 and basic research on cancer immunity. - FY2022-Q2AdvancedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBT005, CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
CBT005 was newly identified as a next-generation pipeline program, clarifying the programs subject to research and development together with CBP-A08, IDO/TDO inhibitors and others. - FY2021RestatedAnnual report
「More recently, based on findings from CBP501 clinical trial data, the company began generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding. Through this initiative, the company obtained the novel candidate compound CBP-A08 and is advancing new basic research intended to form a next-generation pipeline.」
The company continues to generate next-generation candidate compounds and conduct basic research based on CBP501 clinical trial data. - FY2021-Q3RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues research and development on CBP-A08, IDO/TDO inhibitors and other programs as next-generation pipeline programs following CBP501 and CBS9106. - FY2021-Q2SoftenedAnnual report
「Use of proceeds ③ CBP-A08 preclinical trial preparation costs 0 Discontinued」
Although research and development of CBP-A08 itself is continuing, the preclinical trial preparation costs under the financing plan were set at 0 and changed to discontinued. - FY2021-Q1RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company is conducting research and development on CBP-A08, IDO/TDO inhibitors and other programs as next-generation compound pipeline programs following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues research and development on CBP-A08, IDO/TDO inhibitors and other programs as next-generation pipeline programs following CBP501 and CBS9106. - FY2020RestatedAnnual report
「More recently, based on findings from CBP501 clinical trial data, the company began generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding. Through this initiative, the company obtained the novel candidate compound CBP-A08 and is advancing new basic research intended to form a next-generation pipeline.」
The company continues to generate next-generation candidate compounds and conduct basic research focused on cancer immunity, cancer stem cells and other areas based on CBP501 clinical trial data. - FY2020-Q3RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing the next-generation candidate compound CBP-A08 for preclinical trials while taking financial constraints into consideration. - FY2020-Q2RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing the next-generation candidate compound CBP-A08 for preclinical trials while taking financial constraints into consideration. - FY2020-Q1RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing CBP-A08 for preclinical trials while taking financial constraints into consideration. - FY2019-Q3RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing CBP-A08, obtained from its next-generation pipeline, for preclinical trials while taking financial constraints into consideration. - FY2019-Q2RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing the next-generation candidate compound CBP-A08 for preclinical trials while taking financial constraints into consideration. - FY2019-Q1RestatedAnnual report
「With a view to enhancing corporate value over the medium to long term, the company will also prepare for preclinical trials of CBP-A08, a novel candidate compound obtained from the next-generation compound pipeline following CBP501 and CBS9106, while taking financial constraints and other factors into consideration.」
The company continues to pursue a policy of preparing CBP-A08, obtained from its next-generation pipeline, for preclinical trials while taking financial constraints into consideration. - FY2018RestatedAnnual report
「To make the aforementioned CBP-A08 the company's third pipeline program, it must next advance to and clear the preclinical trial stage.」
CBP-A08 has been positioned as an acquired next-generation candidate, while the company has made clear that it must pass preclinical trials before being formally designated as its third pipeline program. - FY2018-Q3RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents. Based on these newly obtained findings, the company is conducting a clinical trial, a Phase 1b trial, in combination with an immune checkpoint inhibitor antibody.」
The company continues to pursue a policy of using findings on cancer immunity and the tumor microenvironment obtained from CBP501 clinical and animal studies in combination trials with an immune checkpoint inhibitor antibody. - FY2018-Q2RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents. Based on these newly obtained findings, the company is conducting a clinical trial, a Phase 1b trial, in combination with an immune checkpoint inhibitor antibody.」
The company continues to pursue a policy of using findings on cancer immunity and the tumor microenvironment obtained from CBP501 clinical and animal studies in combination trials with an immune checkpoint inhibitor antibody. - FY2018-Q1AdvancedAnnual report
「During the cumulative first quarter, we also focused on optimizing a group of new candidate compounds following CBP501 and CBS9106, with a view to enhancing corporate value over the medium to long term. As a result, we obtained the new candidate compound CBP-A08. We will prepare for CBP-A08's preclinical trials in the near future while taking financial constraints and other factors into consideration.」
The company obtained CBP-A08 from its next-generation candidate compounds and advanced to a concrete stage of preparation for preclinical trials in the near future. - FY2017AdvancedAnnual report
「The company continuously searches for and generates novel compounds that could become future development candidates through two drug discovery engines: its proprietary screening focused on differences in the cell-division processes of normal and cancer cells, and the Next-Generation CBP Project based on new findings from CBP501. Through these initiatives, the company currently has multiple next-generation pipeline programs, including CBP-A, CBP-B and IDO/TDO inhibitors.」
The Next-Generation CBP Project was positioned as the second drug discovery engine alongside the company's proprietary screening, and multiple pipeline programs, including CBP-A, CBP-B and IDO/TDO inhibitors, were identified. - FY2017-Q3RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents.」
The company continues to pursue a policy of using findings on cancer immunity and the tumor microenvironment obtained from CBP501 clinical data in basic research and combination studies. - FY2017-Q1RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents.」
Findings on cancer immunity and the tumor microenvironment obtained from CBP501 clinical data continue to be used in basic research. - FY2016First statedAnnual report
「More recently, based on new findings from CBP501 clinical trial data, the company began generating candidate compounds focused on specific mechanisms, such as cancer immunity and cancer stem cells, separately from the cell-based phenotypic screening it has conducted since its founding.」
Findings on the tumor microenvironment, cancer immunity and cancer stem cells obtained from CBP501 clinical data are being used to generate candidate compounds through a separate approach.